Ann: Quarterly Activity Report & Appendix 4C, page-22

Since the volume has dropped off, it's pretty clear to see the price manipulation in the buys and sells.

I think you are bang on the money here, @Titans19. The knowledge of pillar three being a given is very good for us! The evidence supporting the role of Bisantrene impacting AML cancer cells in multiple different ways through inhibition of FTO is comprehensive and building. AML patients that overexpress FTO will be a subset that common chemotherapeutics just can't treat, which leaves a great opportunity for a potent FTO inhibitor. I think that will make FDA approvals much simpler and clearer - clear, new mechanism of action and specific patient population with specific biomarker/s.

I am thinking that people are beginning to wake up to the fact that pillar three is really supportive data of Bisantrene's role as an FTO inhibitor - from an anti-cancer treatment as well as potentially cardiac-safety.